The global pharmaceutical giant Johnson & Johnson has revealed its plans to seek regulatory approval for 10 new drugs by 2019, Bloomberg reports. The company is expecting potential annual sales of $1 billion for each new drug. These blockbuster products would provide a much-needed revenue boost for Johnson & Johnson’s drug division, Janssen Pharmaceutical, which is embroiled not only in fierce ...
J&J Touts Ambitious Drug Pipeline Despite Legal Troubles
Posted June 2, 2015 in Drug and Medical Device Lawsuits | Product News and Recalls
FDA Fast Tracks Boehringer’s Pradaxa Antidote
Posted May 14, 2015 in Product News and Recalls | xarelto
The U.S. Food and Drug Administration (FDA) has given Boehringer Ingelheim’s antidote to its problematic anticoagulant drug Pradaxa a fast-track review, FiercePhrama reports. According to the company, this will make Pradaxa the first “next generation” anticoagulant to receive an FDA-approved antidote.
Last year, the German drug manufacturer Boehringer Ingelheim agreed to pay $650 million to settle roughly 4,000 Pradaxa lawsuits in state and federal courts. Plaintiffs ...
continue reading...Xarelto Lawsuit Filed by California Man
Posted May 7, 2015 in Product News and Recalls | xarelto
A California man has filed a Xarelto lawsuit against multiple pharmaceutical companies for damages allegedly caused by the blood-thinning medication. The plaintiff claims that the defendants, including Johnson & Johnson’s Janssen Pharmaceuticals, overstated the efficacy and safety of Xarelto. The complaint alleges that no antidote exists for Xarelto in the event of hemorrhagic complications.
Like plaintiffs in other Xarelto lawsuits, the California man alleges that the defendants failed ...
continue reading...
The results of AstraZeneca’s recent trials for its blood-thinning drug Brilinta show a decreased risk of post–heart attack heart problems but an increased risk of major bleeding after using the drug. The pharmaceutical company’s large-scale PEGASUS-TIMI 54 trial included 21,000 patients who had suffered at least one heart attack in the past three years. Patients received either a high dose of Brilinta, a low dose of Brilinta, or a placebo drug. All patients ...
Here’s What You Need to Know About Xarelto Lawsuits
Posted April 15, 2015 in Product News and Recalls | xarelto
Expanded Use of Xarelto was rejected by the FDA three times. In June of 2012, the Food and Drug Administration refused to approve the drug designed as a replacement for older-generation blood thinners like warfarin in patients with acute coronary syndrome (ACS). The agency cited concerns over the manufacturers’, Johnson and Johnson and Bayer, failure to present enough information for them to accurately determine the drug’s potential impacts. ...
Xarelto Lawsuit Filed in Rhode Island
Posted March 24, 2015 in Product News and Recalls | xarelto
A Rhode Island man has filed a Xarelto lawsuit against multiple pharmaceutical companies for injuries related to the drug. The plaintiff claimed that the defendants, including Bayer and Johnson & Johnson’s Janssen Pharmaceuticals, received a letter from the FDA in 2013 requesting that they stop improper promotion of their product. The plaintiff further claimed that there is no antidote to the blood-thinning properties of Xarelto, in the ...
